Vaccines pp 121-169 | Cite as

Hepatitis and Polio Vaccines

  • F. Schödel
  • P. Minor
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 133)

Abstract

This chapter provides a brief overview of vaccination strategies against hepatitis viruses and poliomyelitis viruses. For other recent review see MINOR (1991), HOLLINGER and TICEHURST (1996), LEMON and THOMAS (1997), STAPLETON and LEMON (1997) and SCHÖDEL (1998).

Keywords

Paralytic Poliomyelitis Versus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alper CA, Kruskall MS, Marcusbagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ (1989) Genetic prediction of nonresponse to hepatitis-B vaccine. N Engl J Med 321:708–712PubMedCrossRefGoogle Scholar
  2. Asher LV, Binn LN, Mensing TL, Marchwicki RH, Vassell RA, Young GD (1995) Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J Med Virol 47:260–268PubMedCrossRefGoogle Scholar
  3. Ballay A, Levrero M, Tiollais P, Perricaudet M (1987) Hepatitis B adenovirus recombinants as a potential live vaccine. In: Robinson W, Koike K, Will H (eds) Hepadna viruses, vol 70. Liss, New York, pp 481–493Google Scholar
  4. Barker L, Chisari F, McGrath P et al (1973) Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 127:648PubMedCrossRefGoogle Scholar
  5. Beasley R, Hwang L, Stevens C et al (1983) Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind placebo-controlled trial. Hepatology 3:135PubMedCrossRefGoogle Scholar
  6. Blumberg BS, Alter HJ, Visnich S (1965) A ‘new’ antigen in leukemia sera. J Am Med Assoc 191:101–106Google Scholar
  7. Bradley DW, Balayan MS (1988) Virus of enterically transmitted non-A non-B hepatitis. Lancet I:819CrossRefGoogle Scholar
  8. Brown S, Howard C, Zuckerman A, Steward M (1984) Affinity of antibody response in man to hepatitis B vaccines determined with synthetic peptides. Lancet II:184CrossRefGoogle Scholar
  9. Carman WF, Zanetti A, Karayiannis P, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC (1990) A vaccine induced surface mutant of Hbv that is replication competent. Gut 31:A591–A591Google Scholar
  10. Carman WF, Korula J, Wallace L, Macphee R, Mimms L, Decker R (1995a) Fulminant reactivation of hepatitis-B due to envelope protein mutant that escaped detection by monoclonal Hbsag Elisa. Lancet 345:1406–1407CrossRefGoogle Scholar
  11. Carman WF, Thursz M, Hadziyannis S, McIntyre G, Colman K, Gioustoz A, Fattovich G, Alberti A, Thomas HC (1995b) Hepatitis-B E-antigen negative chronic active hepatitis - hepatitis-B. J Viral Hepatitis 2:77–84CrossRefGoogle Scholar
  12. Chan H, Israel M, Garon C, Rowe W, Martin M (1979) Molecular cloning of polyoma virus DNA in Escherichia coli: lambda phage vector system. Science 203:887–892PubMedCrossRefGoogle Scholar
  13. Cheng KC, Smith GL, Moss B (1986) Hepatitis-B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus. J Virol 60:337–344PubMedGoogle Scholar
  14. Chisari FV, Ferrari C (1995) Hepatitis-B virus immunopathogenesis. Annu Rev Immunol 13:29–60PubMedCrossRefGoogle Scholar
  15. Chisari FV, Filippi P, McLachlan A, Milich DR, Riggs M, Lee S, Palmiter RD, Pinkert CA, Brinster RL (1986) Expression of hepatitis-B virus large envelope polypeptide inhibits hepatitis-B surface-antigen secretion in transgenic mice. J Virol 60:880–887PubMedGoogle Scholar
  16. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 244:359–362PubMedCrossRefGoogle Scholar
  17. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Pro Natl Acad Sci USA 91:1294–1298CrossRefGoogle Scholar
  18. Cooremann MP, Schoodermark-Van de Ven EME (1996) Hepatitis C virus: biological and clinical consequence of genetic heterogeneity. Scand J Gastroenterol 31:106–115CrossRefGoogle Scholar
  19. Crowther RA, Kiselev NA, Bottcher B, Berriman JA, Borisova GP, Ose V, Pumpens P (1994) 3-dimensional structure of hepatitis-B virus core particles determined by electron cryomicroscopy. Cell 77:943–950PubMedCrossRefGoogle Scholar
  20. Curtiss R (1990) Attenuated salmonella strains as live vectors for the expression of foreign antigens. In: Woodrow GC, Levine MM (eds) New generation vaccines. Dekker, New York, pp 161–188Google Scholar
  21. Dane D, Cameron C, Briggs M (1970) Virus-like particles in serum from patients with Australia antigen-associated hepatitis. Lancet I:695–698CrossRefGoogle Scholar
  22. Davis H, Michel M-L, Whalen R (1993) DNA based immunization for hepatitis N induces continuous secretion of antigen and high levels of circulating antibody. Hum Mol Genet 2:1847–1851PubMedCrossRefGoogle Scholar
  23. Davis HL, Michel ML, Mancini M, Watkins SC, Schleef M, Whalen RG (1994) Direct gene-transfer in muscle for genetic vaccination against hepatitis-B virus (Hbv). J Cell Biochem 527–527Google Scholar
  24. Emini E, Larson V, Eichberg J, Cinard P, Garsky V, Lee D, Ellis R, Miller W, Anderson C, Gerety R (1989) Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein. J Med Virol 28:7–12PubMedCrossRefGoogle Scholar
  25. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N et al (1992) Lack of prective immunity against reinfection with hepatitis C virus. Science 258:135–140PubMedCrossRefGoogle Scholar
  26. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H (1993) Infectious hepatitis-B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 194:137–148PubMedCrossRefGoogle Scholar
  27. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G, Pilli M, Vitali P, Neri TM, Giuberti T, Fiaccadori F (1992) Fine specificity of the human T-cell response to the hepatitis-B virus pres1 antigen. Gastroenterology 103:255–263PubMedGoogle Scholar
  28. Ferrari C, Penna A, Bertoletti A, Fiaccadori F (1993) Cell-mediated immune-response to hepatitis-B virus nucleocapsid antigen. Arch Virol 8 [Suppl]:91–101Google Scholar
  29. Ferrari G, Place C, Bartlett J, Moody D, Tartaglia J, Paoletti E, Weinhold K (1995) Antigen-specific activation/expansion of human anti-Hiv Ctl using recombinant alvac (canarypox)-based vectors. J Cell Biochem 219–219Google Scholar
  30. Francis D, Hadler S, Thompson S, Maynard J, Ostrow D, Altman N, Braff E, Omalley P, Hawkins D, Judson F, Penley K, Nylund T, Christie G, Meyers F, Moore J, Gardner A, Doto I, Miller J, Reynolds G, Murphy B, Schable C, Clark B, Curran J, Redeker A (1982) The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 97:362–366PubMedGoogle Scholar
  31. Fuerst TR, Yarbough PO, Zhang Y, McAtee P, Tam AW, Lifson J, McCaustland K, Spellbring J, Bradley D, Margolis HS et al (1996) Prevention of hepatitis E using a novel ORF2 subunit vaccine. In: Buison Y, Coursaget P, Kane M (eds) Enterically transmitted hepatitis viruses. France, La Simarre Joue-les-Tours, pp 384–392Google Scholar
  32. Fujii H, Moriyama K, Sakamoto N, Kondo T, Yasuda K, Hiraizumi Y, Yamazaki M, Sakaki Y, Okochi K, Nakajima E (1992) Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 184:1152–1157PubMedCrossRefGoogle Scholar
  33. Fynan E, Webster R, Fuller D, Haynes J, Santoro J, Robinson H (1993) DNA vaccines protective immunization by parenteral mucosal and gene gun inoculations. Proc Natl Acad Sci USA 90:11478–11482PubMedCrossRefGoogle Scholar
  34. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P (1979) Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E coli. Nature 281:646–650PubMedCrossRefGoogle Scholar
  35. Ganem D (1996) Hepadnavridae and their replication. In: Fields BN, Knipe DM, Howley PM et al (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 2703–2737Google Scholar
  36. Gerety R, West D (1990) Current and future hepatitis B vaccines. In: Coursaget P, Tong M (eds) Progress in hepatitis B immunization. John Libbey Eurotext, Paris, pp 215–225 (Colloque INSERM, vol 194 )Google Scholar
  37. Gerlich W, Bruss V (1993) Functions of hepatitis B virus proteins and molecular targets for protective immunity. In: Ellis R (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 41–82Google Scholar
  38. Gilles P, Fey G, Chisari F (1992) Tumor necrosis factor-alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 66:3955–3960PubMedGoogle Scholar
  39. Grady G, Lee V, Prince A et al (1978) Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 138:625PubMedCrossRefGoogle Scholar
  40. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV (1994a) Cytotoxic T-lymphocytes inhibit hepatitis-B virus gene-expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 91:3764–3768CrossRefGoogle Scholar
  41. Guidotti LG, Guilhot S, Chisari FV (1994b) Interleukin-2 and alpha/beta interferon down-regulate hepatitis-B virus gene-expression in-vivo by tumor necrosis factor- dependent and factor-independent pathways. J Virol 68:1265–1270Google Scholar
  42. Guilhot S, Guidotti LG, Chisari FV (1993) Interleukin-2 down-regulates hepatitis-B virus gene-expression in transgenic mice by a posttranscriptional mechanism. J Virol 67:7444–7449PubMedGoogle Scholar
  43. Hadler SC (1991) Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis HS (eds) Viral hepatitis and liver disease. Williams and Wilkins, Baltimore, pp 14–20Google Scholar
  44. Harford N, Cabezon T, Crabeel M, Simoen E, Rutgers A, De Wilde M (1983) Expression of hepatitis B surface antigen in yeast. Dev Biol Stand 54:125–130PubMedGoogle Scholar
  45. Hillemann MR (1993) Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine. In: Ellis RW (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 17–39Google Scholar
  46. Hino K, Okuda M, Hashimoto O, Ishiko H, Okazaki M, Fujii K, Hanada H, Okita K (1995) Glycine-to-arginine substitution at codon-145 of Hbsag in 2 infants born to hepatitis-B E-antigen-positive carrier. Dig Dis Sci 40:566–570PubMedCrossRefGoogle Scholar
  47. Hochstein-Mintzel V, Huber H, Stickl H (1972) Virulenz und Immunogenität eunes modifizierten Vakzinia-Virus (Stamm MVA). Z Immun Forsch 144:140–145Google Scholar
  48. Hogle JM, Chow M, Filman DJ (1985) The three dimensional structure of poliovirus at 29 A resolution. Science 229:1358–1365PubMedCrossRefGoogle Scholar
  49. Hollinger FB, Ticehurst JR (1996) Hepatitis A virus fields. Virology 24:735–782Google Scholar
  50. Houghton M (1996) Hepatitis C Viruses. In: Fields BN, Knipe DM, Howley PM et al (eds) Fields Virology. Lippincott-Raven, Philadelphia, pp. 1035–1058Google Scholar
  51. Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon Y, Koren R, Shouval D (1996) Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing preS antigens: a preliminarv report. J Viral Hepatitis 3:37–42CrossRefGoogle Scholar
  52. HyppiaT, Hovi T, Knowles NJ, Stanway G (1997) Classification of enteroviruses based on molecular and biological properties. J Gen Virol 78:1–11Google Scholar
  53. Inchauspé G (1997) Gene vaccination for hepatitis C. Springer Semin Immunopathol 19:211–221PubMedCrossRefGoogle Scholar
  54. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB et al (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328–1334PubMedCrossRefGoogle Scholar
  55. Ionescu-Matiu I, Kennedy R, Sparrow J, Culwell A, Sanchez J, Melnick L, Dressman G (1983) Epitopes associated with a synthetic hepatitis B surface antigen peptide. J Immunol 130:1947PubMedGoogle Scholar
  56. Israel M, Chan H, Rowe W, Martin M (1979) Molecular cloning of polyoma virus DNA in Eschrichia coli: plasmid vector system. Science 203:883–887PubMedCrossRefGoogle Scholar
  57. Itoh Y, Fujisawa Y (1986) Synthesis in yeast of hepatitis B virus surface antigen modified P31 particles by gene modification. Biochem Biophys Res Commun 141:942–948PubMedCrossRefGoogle Scholar
  58. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M (1986) A synthetic peptide vaccine involving the product of the pre-S (2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 83:9174–9178PubMedCrossRefGoogle Scholar
  59. Jarvis LM, Watson HG, MsOmish F, Peutherer JF, Ludlam CA, Simmonds P (1992) Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 170:1018–1022CrossRefGoogle Scholar
  60. Jung MC, Stemler M, Weimer T, Spengler U, Dohrmann J, Hoffmann R, Eichenlaub D, Eisenburg J, Paumgartner G, Riethmuller G, Will H, Pape GR (1991) Immune- response of peripheral-blood mononuclear-cells to Hbx-antigen of hepatitis-B virus. Hepatology 13:637–643PubMedCrossRefGoogle Scholar
  61. Jung MC, Schraut W, Santantonio T, Spengler U, Eichenlaub D, Eisenburg J, Zachoval R, Hoffmann R, Paumgartner G, Pastore G, Will H, Riethmuller G, Zieglerheitbrock HWL, Pape GR (1993) Increased frequency of Cd8+ Cd45r0+ memory T-lymphocytes in acute hepatitis-B virus-infection. J Hepatol 18:295–300PubMedCrossRefGoogle Scholar
  62. Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, Frosner G, Will H, Pape GR (1995) Activation of a heterogeneous hepatitis-B (Hb) core and E-antigen- specific Cd4 (+) T-cell population during seroconversion to anti-Hbe and anti-Hbs in hepatitis-B virus-infection. J Virol 69:3358–3368PubMedGoogle Scholar
  63. Kao JH, Chen PJ, Lai MY, Wang TH, Chen DS (1995) Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. J Infect Dis 172:261–264PubMedCrossRefGoogle Scholar
  64. Karayiannis P, Jowett T, Enticott M et al (1986) Hepatitis A virus replication in tamarins and host immune response in relation to pathogenesis of liver cell damage. J Med Virol 18:261–276PubMedCrossRefGoogle Scholar
  65. Karron RA, Daemer RJ, Ticehurst JR et al (1988) Evaluation of attenuation of cell- culture-adapted hepatitis A virus in nonhuman primates. In: Zuckerman AJ (ed) Viral hepatitis and liver disease. Liss, New York, pp 74–76Google Scholar
  66. Kobayashi M, Asano T, Utsunomiya M, Itoh Y, Fujisawa Y, Nishimura O, Kato K, Kakinuma A (1988) Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization. J Biotechnol 8:1–22CrossRefGoogle Scholar
  67. Koff RS (1993) Viral hepatitis. In: Schiff L, Schiff ER (eds) Diseases of the liver, pp 492–577Google Scholar
  68. Krugman S, Stevens CE (1994) Hepatitis B vaccine. In: Plotkin S, Mortimer E (eds) Vaccines. Saunders, Chicago, pp 419–437Google Scholar
  69. Krugman S, Giles JP, Hammond J (1967) Infectious hepatitis. J Am Med Assoc 200:365–373CrossRefGoogle Scholar
  70. Krugman S, Giles JP, Hammond J (1971) Viral hepatitis type B (MS-2 strain). Studies on active immunization. J Am Med Assoc 217:41–45CrossRefGoogle Scholar
  71. Kumar U, Monjardino J, Promise HC (1994) Hypervariable region of the hepatitis C virus envelope glycoprotein “E2-NS1” in an agammaglobulinemic patient. Gastroenterology 106:1072–1075PubMedGoogle Scholar
  72. Kurane I, Binn LN, Bancroft WH, Ennis FA (1985) Human lymphocyte responses to hepatitis A virus-infected cells: interferon productio and lysis of infected cells. J Immunol 135:2140–2144PubMedGoogle Scholar
  73. Kuroda S, Itoh Y, Miyazaki T, Otaka-Imai S, Fujisawa Y (1989) Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeast. Gene 78(2):297–308PubMedGoogle Scholar
  74. Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H (1991) Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 9:163–169PubMedCrossRefGoogle Scholar
  75. Lemon SM, Binn LN (1983) Antigenic relatedness of two strains of hepatitis A virus determined by cross-neutralization. Infect Immun 42:418–420PubMedGoogle Scholar
  76. Lemon SM, Binn LN (1993) Serum neutralizing of hepatitis A virus in vitro due to lipid-associated virus. J Gen Virol 148:1033–1039Google Scholar
  77. Lemon SM, Shapiro CN (1994) The value of immunization against hepatitis A. Infect Agents Dis 3:38–49PubMedGoogle Scholar
  78. Lemon SM, Thomas DL (1997) Vaccines to prevent viral hepatitis. N Engl J Med 336(3):196–204PubMedGoogle Scholar
  79. Lemon SM, Ping LH, Day S et al (1991) Immunobiology of hepatitis A virus. In: Hollinger FB, Lemon SM, Margolis HS (eds) Viral hepatitis and liver disease. Williams and Williams, Baltimore, pp 20–24Google Scholar
  80. Lemon SM, Jansen RW, Brown EA (1992) Genetic antigenic and biological differences between strains of hepatitis A virus. Vaccine 10 [Suppl 1]:S40∓S44PubMedCrossRefGoogle Scholar
  81. Li F, Zhuang H, Kolivas S, Locarnini SA, Anderson DS (1994) Persistent and transient antibody responses to hepatitis E virus detected by Western immunoblot using open reading frame 2 and 3 and glutathione S-transferase fusion protiens. J Clin Microbiol 32:2060–2066Google Scholar
  82. Linnen J, Wages J Jr, Zhang-Keck ZY, et al (1996) Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271:505–508PubMedCrossRefGoogle Scholar
  83. Lubeck M, Davis A, Chengalvala M, Natuk R, Morin J, Molnar-Kimber K, Mason B, Bhat B, Mizutani S, Hung P, Purcell R (1989) Immunogenicity and efficacy testing of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA 86:6763–6767PubMedCrossRefGoogle Scholar
  84. MacCallum FO (1947) Homologous serum jaundice. Lancet 2:228Google Scholar
  85. Madalinsky K, Zychowicz C, Gornicki J, Czubkowska I, Skarpetowsk A, Gorecki M, Koren R (1994) Immunogenicity in children of recombinant hepatitis B vaccine containing S pre-S2 and pre-Sl antigens. II. Persistence of antibodies. Polish J Immunol 19:333–340Google Scholar
  86. Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel ML (1993) Induction of antihepatitis-B surface-antigen (Hbsag) antibodies in Hbsag producing transgenic mice - a possible way of circumventing nonresponse to Hbsag. J Med Virol 39:67–74PubMedCrossRefGoogle Scholar
  87. Mancini M, Hadchouel M, Davis HL, Whalen R, Tiollais P, Michel M-L (1996) DNA- mediated immunization breaks tolerance in a transgenic mouse model of hepatitis B surface antigen chronic carriers. Proc Natl Acad Sci USA 93:12496–12501PubMedCrossRefGoogle Scholar
  88. Maneerat Y, Clayson ET, Myint KSA, Young GD, Innis BL (1996) Experimental infection of the laboratory rat with the hepatitis E virus. J Med Virol 48:121–128PubMedCrossRefGoogle Scholar
  89. Mao JS, Chen NL, Huang HY, Chai SA, Dong DX, Coa YY, Zhang HY, Wu DM, Zhang SY (1992) Development of live attenuated hepatitis A vaccine (H2-strain). Chin Med J 105:189–193PubMedGoogle Scholar
  90. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR (1993) The serology of chronic hepatitis-B infection revisited. J Clin Invest 91:2586–2595PubMedCrossRefGoogle Scholar
  91. Mason H, Lam D-K, Arntzen C (1992) Expression of hepatitis B surcace antigen in transgenic plants. Proc Natl Acad Sci USA 89:11745–11749PubMedCrossRefGoogle Scholar
  92. Mayr A, Hochstein-Mintzel V, Stickl H (1975) Abstammung Eigenschaften und Verwendung des attenuierten Vakzinia-Stammes MVA. Infektion 6–14Google Scholar
  93. Mayr A, Stickl H, Müller H, Danner K, Singer H (1978) Pockenimpfstamm MVA: Marker genetische Struktur Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwächten Organismus. Zentralbl Bakt Hyg I Abt Orig B 167:365–390Google Scholar
  94. McAleer W, Buynak E, Maigetter R, Wampler D, Miller W, Hilleman M (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180PubMedCrossRefGoogle Scholar
  95. McAtee CP, Zhang Y, Yarbough PO, Bird T, Fuerst TR, Stone KL, Samander S, Williams KR (1996a) Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry. J Chromatogr B 685:91–104CrossRefGoogle Scholar
  96. McAtee CP, Zhang Y, Yarbough PO, Bird T, Fuerst TR (1996b) Purification of a soluble hepatitis E open reading frame 2-derived protein with unique antigenic properties. Protein Express 8:262–270CrossRefGoogle Scholar
  97. McLachlan A, Milich DR, Raney AK, Riggs MG, Hughes JL, Sorge J, Chisari FV (1987) Expression of hepatitis-B virus surface and core antigens - influences of pre-S and precore sequences. J Virol 61:683–692PubMedGoogle Scholar
  98. McMahon B, Wainwright R (1993) Protective efficacy of hepatitis B vaccines in infants children and adults. In: Ellis R (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 243–261Google Scholar
  99. McMahon G, Ehrlich P, Moustafa Z, McCarthy L, Dottavio D, Tolpin M, Nadler P, Östberg L (1992) Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patient. Hepatology 15:757–766PubMedCrossRefGoogle Scholar
  100. Mendelsohn CL, Wimmer E, Racaniello VR (1989) Cellular receptor for poliovirus: molecular cloning nucleotide sequence and expression of a new member of the immunoglobulin superfamily. Cell 56:855–865PubMedCrossRefGoogle Scholar
  101. Meyer A, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72:1031–1038PubMedCrossRefGoogle Scholar
  102. Michel M-L (1995) Dna-mediated immunization - prospects for hepatitis-B vaccination. Res Virol 146:261–265PubMedCrossRefGoogle Scholar
  103. Michel M-L, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen R (1995) DNA- mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 92:5307–5311PubMedCrossRefGoogle Scholar
  104. Midthun K, Ellerbeck E, Gershman K, Calandra G, Krah D, McCaughtry M, Nalin D, Provost P (1991) Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 163:735–739PubMedCrossRefGoogle Scholar
  105. Milich D (1993) Application of synthetic peptide technology to experimental HBV vaccine design. In: Ellis R (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 351–381Google Scholar
  106. Milich DR (1997) Influence of T-helper subsets and crossregulation in hepatitis B virus infection. J Viral Hepat 4 [Suppl 2]:48–59PubMedCrossRefGoogle Scholar
  107. Milich DR, Chisari FV (1982) Genetic-regulation of the immune-response to hepatitis-B surface-antigen (Hbsag) 1 H-2-restriction of the murine humoral immuneresponse to the a and D determinants Of Hbsag. J Immunol 129:320–325PubMedGoogle Scholar
  108. Milich DR, McLachlan A (1986a) The nucleocapsid of hepatitis B virus is both a T- cell-independent and a T-cell-dependent antigen. Science 234:1398–1401CrossRefGoogle Scholar
  109. Milich DR, McLachlan A (1986b) The nucleocapsid of hepatitis-B virus is both a T- cell independent and a T-cell-dependent antigen. Science 234:1398–1401CrossRefGoogle Scholar
  110. Milich DR, Alexander H, Chisari FV (1983a) Genetic-regulation of the immune- response to hepatitis-B surface- antigen (Hbsag) 3 circumvention of non- responsiveness in mice bearing Hbsag nonresponder haplotypes. J Immunol 130:1401–1407Google Scholar
  111. Milich DR, Lerouxroels GG, Chisari FV (1983b) Genetic-regulation of the immune- response to hepatitis-B surface-antigen (Hbsag) 2. Qualitative characteristics of the humoral immune-response to the a-determinant D-determinant and Y- determinant of Hbsag. J Immunol 130:1395–1400Google Scholar
  112. Milich DR, Lerouxroels GG, Louie RE, Chisari FV (1984) Genetic-regulation of the immune-response to hepatitis-B surface-antigen (Hbsag) 4. Distinct H-2-linked ir genes control antibody-responses to different Hbsag determinants on the same molecule and map to the I-a and I-C subregions. J Exp Med 159:41–56PubMedCrossRefGoogle Scholar
  113. Milich DR, Louie RE, Chisari FV (1985a) Genetic-regulation of the immune-response to hepatitis-B surface-antigen (Hbsag) 5. T-cell proliferative response and cellular interactions. J Immunol 134:4194–4202Google Scholar
  114. Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV (1985b) Distinct H-2-linked regulation of T-cell responses to the pre-S-region and S-region of the same hepatitis-B surface-antigen polypeptide allows circumvention of non- responsiveness to the S-region. Proc Natl Acad Sci USA 82:8168–8172CrossRefGoogle Scholar
  115. Milich DR, Peterson DL, Lerouxroels GG, Lerner RA, Chisari FV (1985c) Genetic- regulation of the immune-response to hepatitis-B surface- antigen (Hbsag) 6 T-cell fine specificity. J Immunol 134:4203–4211Google Scholar
  116. Milich DR, MacLachlan A, Moriarty A, Thornton GB (1987a) Immune responses to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol 139:1223–1231Google Scholar
  117. Milich DR, McLachlan A, Thornton GB, Hughes JL (1987b) A synthetic T-cell site primes antibody production to both the nucleocapsid and the envelope of hepatitis B virus. Nature 330:547–549CrossRefGoogle Scholar
  118. Milich DR, McLachlan A, Stahl S, Wingfield P, Thornton GB, Hughes JL, Jones JE (1988) Comparative immunogenicity of hepatitis B virus core and e antigens. J Immunol 141:3617–3624PubMedGoogle Scholar
  119. Milich DR, Hughes JL, McLachlan A, Langley KE, Thornton GB, Jones JE (1990a) Importance of subtype in the immune-response to the pre-S(2) region of the hepatitis-B surface-antigen 1 T-cell fine specificity. J Immunol 144:3535–3543Google Scholar
  120. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A (1990b) Is a function of the secreted hepatitis-B antigen to induce immunological-tolerance inutero. Proc Natl Acad Sci USA 87:6599–6603CrossRefGoogle Scholar
  121. Milich DR, McLachlan A, Raney AK, Houghten R, Thornton GB, Maruyama T, Hughes JL, Jones JE (1991) Autoantibody production in hepatitis-B E-antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc Natl Acad Sci USA 88:4348–4352PubMedCrossRefGoogle Scholar
  122. Milich DR, Schödel F, Peterson DL, Jones JE, Hughes JL (1995a) Characterization of self-reactive T-cells that evade tolerance in hepatitis-B E-antigen transgenic mice. Eur J Immunol 25:1663–1672CrossRefGoogle Scholar
  123. Milich DR, Wolf SF, Hughes JL, Jones JE (1995b) Interleukin-12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis-B E-antigen transgenic mice. Proc Natl Acad Sci USA 92:6847–6851CrossRefGoogle Scholar
  124. Milich DR, Chen MK, Hughes JL, Jones JE (1998) The secreted hepatitis B eantigen prefentially depletes Th1 cells via Fas: a mechanisms for persistent infection. J Immunol(in press)Google Scholar
  125. Minor PD (1990) Antigenic structure of picornaviruses. In: Compans Rw, Cooper M, Koprowski H et al (eds) Current topics in microbiology and immunology, vol 161. Springer, Berlin Heidelberg New YorkGoogle Scholar
  126. Minor PD (1991) Picornaviridae. In: Francki RIB, Fauquet CM, Knudson DL, Brown F (eds) Classification and nomenclature of viruses. Springer, Vienna New York, pp 320–326 (Archives of virology,suppl 2)Google Scholar
  127. Minor PD (1992) The molecular biology of poliovaccines. J Gen Virol 73:3065–3077PubMedCrossRefGoogle Scholar
  128. Minor PD (1996) Poliovirus. In: Nathanson N et al (eds) Viral pathogenesis. Lippincott-Raven, Philadelphia, pp 555–574Google Scholar
  129. Minor PD, Brown F, King A, Knowles NJ, Lemon S, Martin S, Melnick J, Moore N, Palmenberg A, Rueckert RR, Yin Murphy M (1991) Picornaviridae. In: Francki RIB, Fauquet CM, Knudson DL, Brown F (eds) Classification and nomenclature of viruses; fifth report of the International Committee on Taxonomy of Viruses. Springer, Vienna New York, pp 320–326 (Archives of virology, suppl 2 )Google Scholar
  130. Molnarkimber KL, Jarockiwitek V, Dheer SK, Vernon SK, Conley AJ, Davis AR, Hung PP (1988) Distinctive properties of the hepatitis-B virus envelope proteins. J Virol 62:407–416Google Scholar
  131. Morin J, Lubeck M, Barton J, Conley A, Davis A, Hung P (1987) Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Proc Natl Acad Sci USA 84:4626–4630PubMedCrossRefGoogle Scholar
  132. Moss B, Smith GL, Gerin JL, Purcell RH (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis-B. Nature 311:67–69PubMedCrossRefGoogle Scholar
  133. Murray K, Bruce SA, Hinnen A, Wingfield P, van Eerd PMCA, de Reus A, Schellekens H (1984) Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J 3:645–650PubMedGoogle Scholar
  134. Murray K, Bruce SA, Wingfield P, van Eerd P, de Reus A, Schellekens H (1987) Protective immunisation against hepatitis B with an internal antigen of the virus. J Med Virol 23:101–107PubMedCrossRefGoogle Scholar
  135. Nabel E, Plautz G, Nabel G (1990) Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249:1285–1288PubMedCrossRefGoogle Scholar
  136. Nainan OV, Brinton MA, Margolis HS (1992) Identification of amino acids located in the antibody binding sites of human hepatitis A virus. Virology 191:984–987PubMedCrossRefGoogle Scholar
  137. Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J, Fournillier A, Martynoff G, de Trepo C, Inchauspe G (1997) Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 71:7101–7109PubMedGoogle Scholar
  138. Nardelli-Haefliger D, Kraehenbuhl J-P, Curtiss R III, Schödel F, Potts A, Kelly S, De Grandi P (1996) Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 64:5219–5224PubMedGoogle Scholar
  139. Nassal M (1996) Hepatitis B virus morphogenesis. In: Capron A, Compans RW, Cooper M et al (eds) Current topics in microbiology and immunology, vol 214. Springer, Berlin Heidelberg New York, pp 297–337Google Scholar
  140. Nayersina R, Fowler P, Guilhot S, Missale G, Schlicht H-J, Vitielo A, Chesnut R, Person J, Redeker A, Chisari F (1993) HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659–4671PubMedGoogle Scholar
  141. Neurath AR, Kent SBH, Strick N, Taylor P, Stevens CE (1985) Hepatitis-B virus contains pre-S gene-encoded domains. Nature 315:154–156PubMedCrossRefGoogle Scholar
  142. Neurath AR, Kent SBH, Parker K, Prince AM, Strick N, Brotman B, Sproul P (1986) Antibodies to a synthetic peptide from the pres 120–145 region of the hepatitis-B virus envelope are virus-neutralizing. Vaccine 4:35–37PubMedCrossRefGoogle Scholar
  143. Neurath AR, Seto B, Strick N (1989) Antibodies to synthetic peptides from the pres1 region of the hepatitis-B virus (Hbv) envelope (Env) protein are virus-neutralizing and protective. Vaccine 7:234–236PubMedCrossRefGoogle Scholar
  144. Neurath AR, Strick N, Sproul P, Ralph HE, Valinsky J (1990) Detection of receptors for hepatitis-B virus on cells of extrahepatic origin. Virology 176:448–457PubMedCrossRefGoogle Scholar
  145. Nkowane BM, Wassilak SG, Oversteen WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM (1987) Vaccine associated paralytic poliomyelitis in the United States: 1973 through 1984. J Am Med Assoc 257:1335–1340CrossRefGoogle Scholar
  146. Oehen S, Hengartner H, Zinkernagel R (1991) Vaccination for disease. Science 251:195–198PubMedCrossRefGoogle Scholar
  147. Ohnuma H, Machida A, Okamoto H, Tsuda F, Sakamoto M, Tanaka T, Miyakawa Y, Mayumi M (1993) Allelic subtypic determinants of hepatitis B surface antigen (I and t) that are distinct from d/y or w/r. J Virol 67:937–932Google Scholar
  148. Okamoto H, Yano K, Nozaki Y, Matsui A, Miyazaki H, Yamamoto K, Tsuda F, Machida A, Mishiro S (1992) Mutations within the S gene of hepatitis-B virus transmitted from mothers to babies immunized with hepatitis-B immune globulin and vaccine. Pediatric Res 32:264–268CrossRefGoogle Scholar
  149. Panda SK, Nanda SK, Zafrullah M, Ansari I, Ozdenar MH, Jameel S (1995) An Indian strain of hepatitis E virus (HEV): cloning sequence and expression of structural region and antibody responses in sera from individuals from an area of high-level HEV endemicity. J Clin Microbiol 33:2653–2659PubMedGoogle Scholar
  150. Pasek M, Goto T, Gilbert W, Zink B, Schaller H, MacKay P, Leadbetter G, Murray K (1979) Hepatitis B virus genes and their expression in E coli. Nature 282:575–579PubMedCrossRefGoogle Scholar
  151. Penna A, Bertoletti A, Cavalli A, Valli A, Missale G, Pilli M, Marchelli S, Giuberti T, Fowler P, Chisari FV, Fiaccadori F, Ferrari C (1992a) Fine specificity of the human T-cell response to hepatitis-B virus core antigen. Arch Virol 4 [Suppl]:23–28Google Scholar
  152. Penna A, Fowler P, Bertoletti A, Guilhot S, Moss B, Margolskee RF, Cavalli A, Valli A, Fiaccadori F, Chisari FV, Ferrari C (1992b) Hepatitis-B virus (Hbv)-specific cytotoxic T-cell (Ctl) response in humans - characterization of Hla class-Ii- restricted Ctls that recognize endogenously synthesized Hbv envelope antigens. J Virol 66:1193–1198Google Scholar
  153. Persing DH, Varmus HE, Ganem D (1986) Inhibition of secretion of hepatitis-B surface-antigen by a related presurface polypeptide. Science 234:1388–1391PubMedCrossRefGoogle Scholar
  154. Pincus S, Tartaglia J, Paoletti E (1995) Poxvirus-based vectors as vaccine candidates. Biologicals 23:159–164PubMedCrossRefGoogle Scholar
  155. Ping LH, Lemon SM (1992) Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol 66:2208–2216PubMedGoogle Scholar
  156. Ping LH, Jansen RW, Stapleton JT, Cohen JI, Lemon SM (1988) Identification of an immunodominant antigenic site involoving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci USA 85:8281–8285PubMedCrossRefGoogle Scholar
  157. Pipkin PA, Wood DJ, Racaniello VR, Minor PD (1993) Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J Virol Methods 41:333–340PubMedCrossRefGoogle Scholar
  158. Pol S, Driss F, Michel M-L, Nalpas B, Berthelot P, Brechot C (1994) Specific vaccine therapy in chronic hepatitis B infection (letter to the editor). Lancet 344:342PubMedCrossRefGoogle Scholar
  159. Prince AM (1968) An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60:814–821PubMedCrossRefGoogle Scholar
  160. Prince AM, Brotman B, Huima T, Pascual D, Jaffrey M, Inchauspé G (1992) Immunity in hepatitis C virus infection. J Infect Dis 165:438–443PubMedCrossRefGoogle Scholar
  161. Prince AM, Whalen R, Brotman B (1997) Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15:916–919PubMedCrossRefGoogle Scholar
  162. Provost PJ, Hilleman MR (1979) Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160:213–221PubMedGoogle Scholar
  163. Purcell RH (1996) Hepatitis E virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnich JL, Monath TP, Roizman B, Straus SE (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 2831–2843Google Scholar
  164. Purdy MA, McCaustland KA, Krawczynski K et al (1992) Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recoganized by antibodies in sera from human cases and experimentally infected primates. Arch Virol 123:335–349PubMedCrossRefGoogle Scholar
  165. Redeker A, Mosley J, Gocke D, McKee A, Pollack W (1975) Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med 293:1055–1059PubMedCrossRefGoogle Scholar
  166. Rice CM (1996) Flaviviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM et al (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 931–1034Google Scholar
  167. Robinson H, Hunt L, Webster R (1993) protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid. Vaccine 11:967–960CrossRefGoogle Scholar
  168. Rutgers T, Hauser P, De Wilde M (1993) Potential future recombinant vaccines. In: Ellis R (ed) Hepatitis B virus vaccines in clinical praxis. Dekker, New York, pp 383–407Google Scholar
  169. Sabin AB, Boulger LR (1973) History of the Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1:115–118CrossRefGoogle Scholar
  170. Schödel F (1992) Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv Vir Res 41:409–446CrossRefGoogle Scholar
  171. Schödel (1998) Hepatitis B virus: molecular mechanisms in disease and novel strategies for therapy. In Koshy R, Caselmann WH, (eds) Hepatitis B virus, molecular mechanisms in disease and novel strategies for therapy. Imperial College Press, London (in press)Google Scholar
  172. Schödel F, Sprengel R, Weimer T, Fernholz D, Schneider R, Will H (1989) Animal hepatitis B viruses. Adv Viral Oncol 8:73–102Google Scholar
  173. Schödel F, Milich DR, Will H (1990a) Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol 145:4317–4321Google Scholar
  174. Schödel F,Weimer T, Will H (1990b) HBV: molecular biology and immunology. Biotest Bull 4:63–83Google Scholar
  175. Schödel F, Moriarty AM, Peterson DL, Zheng J, Hughes JL, Will H, Leturcq DJ, McGee JS, Milich DR (1992) The position of heterologous epitopes inserted in hepatitis-B virus core particles determines their immunogenicity. J Virol 66:106–114PubMedGoogle Scholar
  176. Schödel F, Neckermann G, Peterson D, Fuchs K, Fuller S, Will H, Roggendorf M (1993a) Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine 11:624–628CrossRefGoogle Scholar
  177. Schödel F,Peterson D, Zheng J, Jones JE, Hughes JL, Milich DR (1993b) Structure of hepatitis-B virus core and E-antigen - a single precore amino-acid prevents nucleocapsid assembly. J Biol Chem 268:1332–1337Google Scholar
  178. Schödel F, Kelly SM, Peterson DL, Milich DR, Curtiss R (1994a) Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium andSalmonella typhi for oral vaccination. Infect Immun 62:1669–1776Google Scholar
  179. Schödel F, Peterson D, Hughes J, Milich D (1994b) Hepatitis B virus core particles as a vaccine carrier moiety. Int Rev Immunol 11:153–165CrossRefGoogle Scholar
  180. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Evenchen Z, Gorecki M, Gerlich WH (1994a) Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis-B vaccine containing pre-S-1 and pre-S-2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453–1459CrossRefGoogle Scholar
  181. Shouval D, Ilan Y, Hourvitz A, Mosseri R, Solomon A, Zychowicz A, Gornicki J, Czubkowska I, Madalinski K, Burczynska B, Adler R, Gorecki M, Koren R (eds) (1994b) Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing preS2 and preSl antigens: a preliminary report. Viral Hepatitis Liver DisGoogle Scholar
  182. Siegl G,Weitz M (1993) Pathogenesis of hepatitis A: persistent viral infection as basis of an acute disease? Microb Pathog 14:1–8PubMedCrossRefGoogle Scholar
  183. Simons JN, Leary TP, Dawson GJ, et al (1995) Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1:564–569PubMedCrossRefGoogle Scholar
  184. Sitrin R, Wampler D, Ellis R (1993) Survey of licensed hepatitis B vaccines and their production processes. In: Ellis R (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 83–101Google Scholar
  185. Sjögren MH, Purcell RH, McKee K, Binn L, Macarthy P, Ticehurst J, Feinstone S, Caudil J, See A, Hoke C et al (1992) Clinical and laboratory observations following oral or intramuscular administation of a live attenuated hepatitis A vaccine candidate. Vaccine 10 [Suppl 1]:S135–S137PubMedCrossRefGoogle Scholar
  186. Standring D, Ou J, Rutter W (1986) Assembly of viral particles in Xenopus oocytes: pre-surface-antigens regulate secretion of the hepatitis B viral surface envelope particle. Proc Natl Acad Sci USA 83:9338–9342PubMedCrossRefGoogle Scholar
  187. Stapleton JT (1995) Host immune response to hepatitis A virus. J Infect Dis 171 [Suppl 1]:S9–S14PubMedCrossRefGoogle Scholar
  188. Stapleton JT, Lemon SM (1987) Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol 61:491–498PubMedGoogle Scholar
  189. Stapleton JT, Lemon SM (1997) New Vaccines Against Hepatitis A. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS (ed) New generation vaccines. Marcel Dekker, New York, pp 571–585Google Scholar
  190. Stevens C, Beasley R, Tsuji J, Lee W (1975) Vertical transmission of hepatitis B in Taiwan. N Engl J Med 292:771–774PubMedCrossRefGoogle Scholar
  191. Stickl H, Hochstein-Mintzel V, Mayr A, Huber H, Schäfer H, Holzner A (1974) MVA- Stufenimpfung gegen Pocken Klinische Erprobung des attenuierten Pocken- Lebendimpfstoffes Stamm MVA. Dtsch Med Wochenschr 99:2386–2392PubMedCrossRefGoogle Scholar
  192. Stokes J Jr, Neefe J (1945) The preventio and attenuation of infectious hepatitis by gamma globulin. JAMA 127:144–145Google Scholar
  193. Suzuki H, Iino S, Shiraki K, Akahane Y, Okamoto H, Domoto K, Mishiro S (1994) Safety and efficacy of a recombinant yeast-derived pre-S2+S containig hepatitis B vaccine (TGP-943): phase 1 phase 2 and 3 clinical testing. Vaccine 12:1090–1096PubMedCrossRefGoogle Scholar
  194. Szmuness W, Stevens C, Harley E, Zang E, Oleszko W, William D, Sadovshy R, Morrison J, Kellner A (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 303:833–841PubMedCrossRefGoogle Scholar
  195. Tacket C, Kelly S, Schödel F, Losonsky G, Nataro J, Edelman R, Levine M, Curtiss R III Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the ASD balanced-lethal system (in preparation)Google Scholar
  196. Tacket CO, Losonsky G, Lubeck M, Davis A, Mizutani S, Horwith G, Hung P, Edelman R, Levine MM (1992) Initial safety and immunogenicity studies of an oral recombinant adeno-hepatitis B vaccine. Vaccine 10:673–676PubMedCrossRefGoogle Scholar
  197. Tang D-C, De Vit M, Johnston S (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152–154PubMedCrossRefGoogle Scholar
  198. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, Vanderhoeven J, Meignier B, Riviere M, Languet B, Paoletti E (1992) Nyvac - a highly attenuated strain of vaccinia virus. Virology 188:217–232PubMedCrossRefGoogle Scholar
  199. Taylor JM (1996) Hepatitis delta virus and its replication. In: Fields BN, Knipe DM, Howley PM et al (eds) Fields virology, vol 2,, 3rd edn. Lippincott-Raven, Philadelphia; pp 2809–2818Google Scholar
  200. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E (1988) Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6:497–503PubMedCrossRefGoogle Scholar
  201. Thanavala Y, Yang Y, Lyons P, Mason F, Arntzen C (1995) Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 92:3358–3361PubMedCrossRefGoogle Scholar
  202. Thoma H, Hemmerling A, Koller E, Kaper G (1991) Does preS2 have the same effect in improving the HBV immune response as preSl. In: Hollinger F, Lemon S, Margolis H (eds) Viral hepatitis and liver disease. Williams and Wilkins, Baltimore, pp 736–741Google Scholar
  203. Thornton G, Milich D, Chisari F, Mitamura K, Kent S, Neurath R, Purcell R, Gerin J (1987) Immune responses in primates to the pre-S2 region of hepatitis-B surface antigen: Identification of a protective determinant. In: Chanock R, Lerner R, Brown F, Ginsberg H (eds) Vaccines 87. Cold Spring Harbor Laboratory, Cold Spring HarborGoogle Scholar
  204. Thornton G, Moriarty A, Milich D, Eichberg J, Purcell R, Gerin J (1989) Protection of chimpanzees from hepatitis-B virus infection after immunization with synthetic peptides: identification of protective epitopes in the pre-S region. In: Brown F, Chanock R, Ginsberg H, Lerner R (eds) Vaccines 89. Cold Spring Harbor Laboratory, Cold Spring HarborGoogle Scholar
  205. Tian-Cheng L, Yoshio Y, Kenji S, Masashi T, Mohammed A, Azeez R, Toshikazu U, Naokazu T, Tatsuo M (1997) Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71:7207–7213Google Scholar
  206. Tiollais P, Pourcel C, Dejean A (1985) The hepatitis B virus. Nature 317:489–495PubMedCrossRefGoogle Scholar
  207. Tron F (1994) Hepatitis B virus recombinant vaccines: achievement and progress. In: Kurstak E (ed) Modem vaccinology. Plenum, New York, pp 153–167Google Scholar
  208. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS (1992) Acute exacerbations of chronic type B-hepatitis are accompanied by increased T-cell responses to hepatitis-B core and E-antigens - implications for hepatitis-B E-antigen seroconversion. J Clin Invest 89:87–96PubMedCrossRefGoogle Scholar
  209. Tsarev SA, Emerson SU, Tsareva TS et al (1993) Variation in course of hepatitis E in experimentally infected cynomolgus monkeys. J Infect Dis 167:1302–1306PubMedCrossRefGoogle Scholar
  210. Tsarev SA, Tsareva TS, Emerson SU et al (1994) Successful passive and active immunization of cynomolgous monkeys against hepatitis E. Proc Natl Acad Sci USA 91:10198–10202PubMedCrossRefGoogle Scholar
  211. Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL, Robinson R, Gorbalenya AE, Purcell RH (1996) Prospects for prevention of hepatitis E. In: Buisson Y, Coursaget P, Kane M (eds) Enterically-transmitted hepatitis viruses. France, La Simarre Tours, pp 373–383Google Scholar
  212. Ulmer J, Donnelly J, Parker S, Rhodes G, Felgner P, Gromkowski S, Deck R, DeWitt C, Friedman A, Hawe L, Leander K, Martinez D, Perry H, Shiver J, Montgomery D, Liu M (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749PubMedCrossRefGoogle Scholar
  213. Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman H, Rutter W (1979) Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280:815–819PubMedCrossRefGoogle Scholar
  214. Valenzuela P, Medina A, Rutter W, Ammerer G, Hall B (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298:347–350PubMedCrossRefGoogle Scholar
  215. Vallbracht A, Hoffmann L, Wurster KG, Flehmig B (1984) Persistend infection of human fibroblasts by hepatitis A virus. J Gen Virol 65:609–615PubMedCrossRefGoogle Scholar
  216. Vallbracht A, Maier K, Stierhof YD, Wiedmann KH, Flehmig B, Fleischer B (1989) Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 160:209–217PubMedCrossRefGoogle Scholar
  217. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E (1998) Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 338 (5):286–290PubMedCrossRefGoogle Scholar
  218. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, Lafond R, Yuan LL, Chisari FV, Furze J, Bartholomeuz R, Chesnut RW (1995) Development of a lipopeptide based therapeutic vaccine to treat chronic Hbv infection 1. Induction of a primary cytotoxic T-lymphocyte response in humans. J Clin Invest 95:341–349PubMedCrossRefGoogle Scholar
  219. Wallace LA, Echevarria JE, Echevarria JM, Carman WF (1994) Molecular characterization of envelope antigenic variants of hepatitis-B virus from Spain. J Infect Dis 170:1300–1303PubMedCrossRefGoogle Scholar
  220. Wang B, Ugen K, Srikantan V, Agadjanyan M, Dang K, Refaeli Y, Sato A, Boyer J, Willams W, Weiner D (1993) Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:4156–4160PubMedCrossRefGoogle Scholar
  221. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carmann W, Thomas HC (1992) Loss of the common “A” determinant of hepatitis B antigen by a vaccine-induced escape mutant. J Clin Invest 90:2543–2547PubMedCrossRefGoogle Scholar
  222. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G et al (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 453–457PubMedCrossRefGoogle Scholar
  223. Werzberger A, Kuter B, Nalin D (1998) N Engl J Med (publication pending )Google Scholar
  224. West D (1993) Scope and design of hepatitis B vaccine clinical trials. In: Ellis R (ed) Hepatitis B vaccines in clinical practice. Dekker, New York, pp 159–177Google Scholar
  225. Whittle H, Bradley A, McLauchlan K, Ajdukiewicz A, Howard C, Zuckerman A, McGregor I (1983) Hepatitis B virus infection in two Gambian villages. Lancet i: 1203–1206CrossRefGoogle Scholar
  226. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A (1995) Long-term efficacy of continuing hepatitis-B vaccination in infancy in 2 Gambian villages. Lancet 345:1089–1092PubMedCrossRefGoogle Scholar
  227. Wilde MD, Rutgers T, Cabezon T, Hauser P, Opstaal OV, Harford N, Wijnendaele FV, Desmons P, Comberbach MPR, Safary A, Wiedermann G, Ambrusch FP, Voet Delem A, Petre J (1991) PreS containing HBsAg particles from Saccharomyces cerevisae: production antigenicity and immunogenicity. In: Hollinger F, Lemon S, Margolis H (eds) Viral hepatitis and liver disease. Williams and Wilkins, Baltimore, pp 732–736Google Scholar
  228. Will H, Cattaneo R, Hock H, Darai G, Schaller H, Schellekens H (1982) Cloned HBV DNA causes hepatitis in chimpanzees. Nature 299:740–742PubMedCrossRefGoogle Scholar
  229. Winokur PL, McLinden JH, Stapleton JT (1991) The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles. J Virol 65:5029–5036PubMedGoogle Scholar
  230. Wolff J, Malone R, Williams P, Chong W, Ascadi G, Jani A, Felgner P (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  231. World Health Organization (1994) WHO meeting on nucleic acid vaccines. Vaccine 12:1491–1567CrossRefGoogle Scholar
  232. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M (1994) Naturally-occurring escape mutants of hepatitis- B virus with various mutations in the S-gene in carriers seropositive for antibody to hepatitis-B surface-antigen. J Virol 68:2671–2676PubMedGoogle Scholar
  233. Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R (1997) Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-Sl and Pre-S2 antigens in neonates. Pediatr Infect Dis J 16:587–592PubMedCrossRefGoogle Scholar
  234. Yap I, Guan R, Chan SH (1995) Study on the comparative immunogenicity of a recombinant-Dna hepatitis-B vaccine containing pre-S components of the Hbv coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 10:51–55PubMedCrossRefGoogle Scholar
  235. Zheng J, Schödel F, Peterson DL (1992) The structure of hepadnaviral core antigens - identification of free thiols and determination of the disulfide bonding pattern. J Biol Chem 267:9422–9429PubMedGoogle Scholar
  236. Zimmerman RK, Ruben FL, Ahwesh ER (1997) Hepatitis B virus infection hepatitis B vaccine and hepatitis B immune globulin. J Fam Pract 45:295–315PubMedGoogle Scholar
  237. Zuckermann JN, McDermott A, Craig FM, Williams A, Madrigal J, Zuckerman A (1996) Immunogenicity of a novel pre-Sl/pre-S2? S hepatitis B vaccine in non- responders and high resolution analysis of HLA haplotypes. In: IXth Triennal international symposium on viral hepatitis and liver disease, Rome ItalyGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • F. Schödel
  • P. Minor

There are no affiliations available

Personalised recommendations